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Malignant tumors display remarkable heterogeneity to the extent that even at the same
tissue site different types of cells with varying genetic background may be found. In
contrast, a relatively consistent marker the scavenger receptor type B1 (SR-B1) has
been found to be consistently overexpressed by most tumor cells. Scavenger Receptor
Class B Type I (SR-BI) is a high density lipoprotein (HDL) receptor that facilitates the
uptake of cholesterol esters from circulating lipoproteins. Additional findings suggest
a critical role for SR-BI in cholesterol metabolism, signaling, motility, and proliferation
of cancer cells and thus a potential major impact in carcinogenesis and metastasis.
Recent findings indicate that the level of SR-BI expression correlate with aggressiveness
and poor survival in breast and prostate cancer. Moreover, genomic data show that
depending on the type of cancer, high or low SR-BI expression may promote poor
survival. This review discusses the importance of SR-BI as a diagnostic as well as
prognostic indicator of cancer to help elucidate the contributions of this protein to
cancer development, progression, and survival. In addition, the SR-B1 receptor has
been shown to serve as a potential gateway for the delivery of therapeutic agents when
reconstituted high density lipoprotein nanoparticles are used for their transport to cancer
cells and tumors. Opportunities for the development of new technologies, particularly in
the areas of cancer therapy and tumor imaging are discussed.
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BACKGROUND
High density lipoproteins (HDLs) have been designated as “the good cholesterol” carriers due to
their athero-protective effects. The beneficial impact of elevated HDL levels have been attributed
to several factors, including participation in reverse cholesterol transport, anti-oxidant effects and
anti-inflammatory functions (Miller et al., 1985; Navab et al., 1991, 2000a,b, 2001). During reverse
cholesterol transport, HDL removes excess peripheral cholesterol and channels it toward the liver
for disposal (or re-cycling), facilitated, at least in part, by the Scavenger Receptor, Class B, Type 1
(SR-B1; Figure 1A). Decreased plasma cholesterol levels (especially, lower HDL cholesterol levels)
have been found in several groups of cancer patients representing a broad range of malignancies
(Rose et al., 1974; Fiorenza et al., 2000; Shah et al., 2008; Muntoni et al., 2009). Regarding the
mechanism of the lowering of HDL cholesterol levels in cancer patients, several reports found over-
expression of the SR-B1 receptors as the potential cause (Lacko et al., 2002; Mooberry et al., 2010;
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FIGURE 1 | The physiological role of HDL is to clear the excess tissue cholesterol through the liver. (A) In phase 1, the cholesterol-rich HDL is captured by
the SR-B1 receptor on the surface of the cell. (B) In phase 2, HDL delivers its cholesteryl ester cargo through SR-B1 directly into the cytoplasm. (C) In phase 3, the
depleted HDL particle is released into the blood. The majority of cancer patients have lower than normal blood cholesterol especially HDL (or good) cholesterol.
Images courtesy of Andras Lacko; full animation video is available at https://www.youtube.com/watch?v=q0YiPqmsXRg.
Shahzad et al., 2011; de Gonzalo-Calvo et al., 2015; Li et al.,
2016; Yuan et al., 2016). Consequently, one of the key issues
to be resolved is the extent to which the increased functionality
of the SR-B1 receptor may be responsible for the markedly
lower HDL cholesterol levels found in most cancer patients
as the precise role of the SR-B1 receptor in the development
of malignant and metastatic growth is yet to be delineated.
Findings from a number of studies (Cruz et al., 2013; Yang
et al., 2013) suggest that the delivery of cholesterol to rapidly
growing malignant cells, facilitated by the overexpressed SR-B1
receptor, is essential for at least some tumor types. Cao et al.
(2004) on the other hand showed that breast cancer xenografts
could not develop when the carboxy terminal of the CLA-1 (SR-
B1) receptor was mutated while other studies indicated that the
carboxy terminal region of the SR-B1 receptor was not directly
involved in cholesterol transport (Connelly et al., 2001; Cao
et al., 2004). While the mechanism whereby the SR-B1 receptor
contributes to carcinogenesis is not yet clear, expression of the
SR-B1 receptor may signal the prognosis and survival prospects
of cancer patients and thus could have a role as an important
diagnostic biomarker for specific malignancies.
HDL METABOLISM AND RECEPTORS
WITH SPECIAL EMPHASIS ON
SCAVENGER RECEPTORS
The precursor to circulating HDL is produced in the liver and
subsequently released into the circulation. These are cholesterol-
poor, discoidal structures, composed primarily of apolipoprotein
A-I (apo A-I) and phospholipid (Hamilton et al., 1976). Next
the ATP-binding cassette protein, ABCA-1, facilitates the loading
of the nascent discoidal HDL with excess cholesterol from
peripheral tissues. The cholesterol progressively accumulated in
HDL is then esterified by Lecithin-Cholesterol Acyltransferase
(LCAT) to produce mature spherical HDL particles with an
expanded core region, containing primarily cholesteryl esters.
Although apo A-I is the main protein component of HDL, it
acquires other apolipoproteins including apo A-II, apo A-IV,
apo C-III or apo E, from other lipoproteins. The respective
apolipoproteins may facilitate the interactions of HDL with
several lipoprotein receptors (Alaupovic et al., 1972; Scanu, 1972;
Scanu and Wisdom, 1972; Schmitz and Mollers, 1994; Fidge,
1999).
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Unlike the delivery of Low density lipoprotein (LDL)
cholesterol that involves endocytic uptake of the entire
lipoprotein particle, most of the cholesterol from HDL undergoes
a process termed selective lipid uptake, facilitated by the SR-B1
receptor, involving only the removal of cholesteryl esters from
the HDL complex (Figure 1B). The subsequent steps involve the
release of the now cholesterol-depleted HDL via a process called
retroendocytosis (Pagler et al., 2006; Sun et al., 2006). The protein
component of HDL is thus not internalized, but remains (at least
transiently) bound to the plasma membrane (Figure 1C).
A plasma membrane protein, SR-B1, is the murine HDL
receptor (Acton et al., 1996). The human homolog is termed
CD36-and-LIMPII analogous-1 (CLA-1). The human HDL
receptor is composed of 509 amino acids and has an apparent
molecular weight of 85 kDa including carbohydrate moieties that
are attached to the polypeptide portion via N-linked glycosylation
(Calvo et al., 1997). Expression of SR-B1 is most prominent in
tissues involved in cholesterol metabolism or steroid hormone
synthesis, including the liver, adrenal glands, ovaries, and testes
(Landschulz et al., 1996; Calvo et al., 1997; Arenas et al., 2004;
Shahzad et al., 2011). However, besides acting as an HDL receptor,
facilitating selective lipid uptake from HDL, SR-B1 has also been
shown to be a high-affinity receptor for LDL, VLDL, oxidized
LDL, and acetylated LDL (Calvo et al., 1997).
The mechanism of selective lipid uptake by SR-B1 has
yet to be described in detail. The known domains of SR-B1
consist of a short N-terminal intracellular region, an N-terminal
transmembrane domain, a cysteine-rich region that forms an
extracellular loop, a C-terminal transmembrane domain, and
a C-terminal intracellular domain (Krieger, 1999). It has been
postulated that SR-B1 forms a “hydrophobic channel” to allow
passage of lipophilic HDL components into the cell (Rodrigueza
et al., 1999). Reports in the literature have attempted to
delineate the respective functional domains and their specific
contributions to HDL binding, and selective lipid uptake. Studies
creating chimeric receptors between domains of CD36 and SR-
B1 have shown that neither the N-terminal nor C-terminal
transmembrane and cytoplasmic domains of SR-B1 are necessary
for selective lipid uptake. The function of selective lipid uptake
was found to be the task of the extracellular domain of SR-
B1 (Connelly et al., 2001). The extracellular domain of SR-B1
contains six cysteine residues highly conserved among mouse,
rat, hamster, rabbit, pig, cow, dog, and human isoforms (Hu et al.,
2011). In a mutational analysis, some of these cysteine residues
were found to interfere with cell surface localization and selective
lipid uptake, possibly due to the formation of aberrant disulfide
bonds and protein misfolding (Hu et al., 2011).
EXPRESSION AND POTENTIAL ROLES
OF THE SR-B1 RECEPTOR IN CANCER
CELLS AND TUMORS
Cholesterol Metabolism
A breast cancer cell line HBL-100, was shown to take up
cholesteryl esters (CE) selectively through SR-B1. The cells
internalized CE in a dose-dependent manner in response to the
HDL3 concentration. No increase in uptake of CE was observed
with adrenocorticotropic hormone, but down-regulation of
SR-B1 expression and decreased CE uptake were seen with
phorbol 12-myristate 13-acetate (PMA). The cholesteryl esters
were subsequently hydrolyzed by hormone sensitive lipase
(Pussinen et al., 2000). A study in patients with three subtypes
of breast cancer found that CE accumulation corresponded
with increases in cholesterol esterification and the expression
of the LDL receptor and SR-B1 (de Gonzalo-Calvo et al.,
2015). In patients with Her-2 breast cancer (ER−/PR−/HER2+)
or triple negative breast cancer (ER−/PR−/HER2−), tumor
samples with enriched cholesteryl ester accumulation were
associated with increased expression of the cell proliferation
marker, Ki-67, thus indicating the potential for enhanced tumor
proliferation and progression. However, the third subtype,
estrogen and progesterone receptor positive luminal-A breast
cancer (ER+/PR+/HER2−) did not show increased intracellular
cholesteryl esters or increased Ki-67 expression (de Gonzalo-
Calvo et al., 2015). Because of the differential cholesteryl
ester accumulation and expression of SR-B1 in varying grades
and subtypes of breast cancer that links to proliferation and
progression, more research into cholesterol metabolism in cancer
subtypes is warranted.
In a study involving high grade metastatic prostate cancer
increased accumulation of CE into lipid droplets was observed.
The CE accumulation was found to be in response to the loss of
the tumor suppressor PTEN, activation of the mTOR pathway
and downstream activation of SREBP, and the up-regulation
of LDL receptor (Yue et al., 2014). This study examined only
uptake of LDL and the LDL receptor, not selective CE uptake
through SR-B1. However, the SR-B1 gene does contain two
Sterol Regulatory Elements (SREs) that are activated by SREBP
(Lopez and McLean, 1999). In a report on high Gleason grade
primary prostate cancer, SR-B1 mRNA and protein expression
were found to be high, unlike the LDL receptor (Schörghofer
et al., 2015). The link between SR-B1 expression and cholesteryl
ester accumulation could provide the link between androgen
independence and advanced prostate cancer (Twiddy et al., 2012;
Schörghofer et al., 2015).
Signaling Mechanisms
High density lipoprotein, beyond binding to SR-B1 and
completing reverse cholesterol transport has also been found to
subsequently activate the PI3K/Akt and MAPK pathways (Danilo
et al., 2013). SR-B1 has been investigated as a mediator of cell
signaling events in atherosclerosis (Al-Jarallah and Trigatti, 2010;
Saddar et al., 2010). SR-B1 has been found to be highly expressed
in several different types of tumors including breast, ovarian,
colorectal, pancreatic cancer (Shahzad et al., 2011) and prostate
cancer (Schörghofer et al., 2015) with relatively low expression in
most healthy tissue (Rhainds and Brissette, 2004). Although SRB1
has been found to have a protective role in atherosclerosis, high
expression of SR-B1 has also been linked to the rapid progression
and aggressiveness of certain types of cancer, while the exact
underlying mechanisms and downstream cell signaling events of
SR-B1 are presently not fully understood.
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Hypercholesterolemia and excessive consumption of a
cholesterol or fat rich diet have been recognized as risk factors
for prostate cancer. Additional studies have also shown that
the aggressive form of the disease is likely to be associated with
the intracellular accumulation of esterified cholesterol (Shimizu
et al., 1991; Bravi et al., 2006; Yue et al., 2014). While cellular
cholesterol uptake is known to be facilitated by the SR-B1 and
the LDL receptor (Acton et al., 1996; Krieger, 1999; Chen and
Hughes-Fulford, 2001; Rohrl and Stangl, 2013). SR-B1 has been
found to be highly expressed in prostate cancer cells (Connelly
and Williams, 2004; Kraemer, 2007; Connelly, 2009; Hoekstra
et al., 2009). Twiddy et al. (2012) have found that protein
expression of SR-B1 was significantly increased upon progression
to castration-resistance stage in the LNCaP xenograft model
(Leon et al., 2010). Even higher expression of SR-B1 has been
reported in C4-2 cells compared to LNCaP cells, suggesting a
role for SR-B1 in the development and progression of advanced
prostate cancer (Twiddy et al., 2012). These findings indicate
that the castration resistant prostate cancer cells might be able
to survive in a low androgen environment by increasing their
demand for cholesterol influx for cellular processes (Wu et al.,
1994; Leon et al., 2010).
The Akt signaling pathway is activated in 40% of breast
cancers (Bellacosa et al., 2005). Studies conducted by Danilo
et al. (2013) showed that HDL (100 µg/ml) can trigger the
activation of Erk1/2 and Akt pathways in breast cancer cells.
Their studies in MDA-MB-231 cells have shown that knockdown
of the SR-B1 receptor (via lentiviral transduction of SR-B1 shRNA
or pharmacological inhibition of SR-B1 in the presence of HDL)
mitigated the activation of the expression of the Akt signaling
molecule. Whereas, the knockdown of SR-B1 receptor in MCF-
7 cells showed a marked decrease in the activation of Akt and
the Erk1/2 pathway. These findings support the hypothesis that
the binding of HDL to SR-B1 may be involved in the regulation
of these signaling pathways. Additionally, the studies of Danilo
et al. (2013) have also shown that knockdown of SR-B1 in MDA-
MB-231 cells triggered a reduction in the intracellular cholesterol
levels, in concurrence with the studies of Assanasen et al. (2005)
showing that SR-B1 modulated signal transduction could be
linked to cellular cholesterol flux (Danilo et al., 2013).
Proliferation
Cancer cells are considered to be dependent on cholesterol for
their proliferation and rapid progression (Gospodarowicz et al.,
1982; Johnson et al., 1991; Cruz et al., 2013). Comparative
analysis of SR-B1 expression in breast tissues revealed a high
expression of SR-B1 in breast tumors compared to the healthy
surrounding tissue (Cao et al., 2004; Shahzad et al., 2011).
Additionally, reports from multiple studies, conducted with
several cancer cells revealed that HDL can enhance their capacity
for proliferation and migration (Gospodarowicz et al., 1982;
Jozan et al., 1985; Rotheneder and Kostner, 1989; Pussinen et al.,
2000; Pan et al., 2012a,b). Studies conducted by Danilo et al.
(2013) in MDA-MB-231 (triple negative breast cancer cells)
have shown that pharmacological inhibition of SR-B1 (through
BLT-1) or knockdown of SR-B1 resulted in a reduction in
cell proliferation perhaps via a decreased activation of the Akt
signaling pathway.
Migration
High density lipoprotein, a carrier of plasma cholesterol has also
been found to be a signaling molecule inducing the migration
of endothelial cells by activating the Akt and MAPK pathways
(Danilo et al., 2013). Similarly, Danilo et al. (2013) have shown
that HDL can induce the migration of MCF-7 and MDA-
MB-231 cells. In addition, Danilo et al. (2013) performed SR-
B1 knockdown in MDA-MB-231 cells and found a significant
decrease in their potential for migration (1.65-fold) compared
to control cells. These findings are in accordance with studies
conducted in nasopharyngeal carcinoma cells, where knockdown
of SR-B1 resulted in reduced migration in 5-8F shSR-B1-treated
cells compared to control cells (Zheng et al., 2013).
Angiogenesis
High density lipoprotein was shown to induce endothelial
tube formation and angiogenesis in human coronary artery
endothelial cells through a MAPK pathway (Miura et al., 2003).
Seetharam et al. (2006) showed that endothelial cell migration
was activated by PI3K/Akt/MAPK pathways mediated by SR-B1.
This effect was impaired in SR-B1 knockout mice (Seetharam
et al., 2006). In hypoxic conditions, HDL stimulated the PI3K/Akt
pathway through SR-B1, resulting in stabilization of hypoxic
inducible factor-1α (HIF-1α; Figure 2). The result is activation
of transcription of VEGF and induction of angiogenesis, which
could be inhibited by transduction with a lentivirus containing
a shRNA against SR-B1 (Tan et al., 2014). Mutational analysis
of SR-B1 found that changing a critical glutamine residue
in one of the transmembrane domains disrupted p38/MAPK
signaling. In a mouse model system, the mutant SR-B1 was not
capable of increasing endothelial cell abundance or stimulating
angiogenesis, even with HDL activation (Saddar et al., 2013). In
inflammatory-mediated angiogenesis, HDL and SR-B1 appear to
play an inhibitory role (McGrath et al., 2009).
Like HDL and SR-BI, the signaling mechanism for
angiogenesis is often utilized by tumors via PI3K/Akt activation
and the HIF-1α pathway (Karar and Maity, 2011). Several studies
have identified a link between SR-BI and the PI3K/Akt pathway,
but the mechanism where by SR-BI impacts angiogenesis is not
clear. Danilo et al. (2013) found that mice bearing a MDA-MB-
231 xenografts had significantly increased microvessel density
in the control tumor when compared to the SR-B1 knockdown
tumor. In the TRAMP mouse model of prostate cancer, mice
fed a high-fat, high-cholesterol Western-style diet had decreased
plasma HDL cholesterol levels, increased tumor expression of
SR-B1 and increased tumor angiogenesis (Llaverias et al., 2010).
These studies in cholesterol metabolism, signaling mech-
anism, proliferation, migration, and angiogenesis have been
conducted with cancer cells, tumor xenograft in mouse models,
and patient tumor samples of prostate and breast cancer. The
majority of the findings reported in the literature regarding SR-
B1 and cancer focus on breast and prostate cancer. Expanding
the focus of these studies to other types of tumors would allow
the elucidation of the role of the SR-B1 receptor and the related
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FIGURE 2 | SR-B1 signaling pathway for normal hypoxia-induced
angiogenesis. Interaction of HDL and SR-B1 activates the PI3K/Akt pathway
leading to HIF-1α translocation to the nucleus and transcription of VEGF. HDL
treatment and over-expression of SR-B1 has been shown to activate the
PI3K/Akt pathway in tumor cells and stimulate proliferation and migration.
signaling mechanisms governing cancer proliferation, migration,
invasion, and angiogenesis.
SR-B1 AS A PREDICTOR OF TUMOR
PROGNOSIS AND SURVIVAL
Scavenger Receptor Class B Type 1 (SR-B1) is a HDL receptor
that facilitates the uptake of cholesterol esters from circulating
lipoproteins (primarily from HDL). Recent findings indicate that
the level of SR-B1 expression is correlated with aggressiveness
and poor survival in breast and prostate cancer (Schörghofer
et al., 2015; Yuan et al., 2016). Moreover, genomic data show that
depending on the type of cancer, high or low SR-B1 expression
may promote poor survival. This section focuses on SR-B1 as
a diagnostic as well as prognostic biomarker for specific types
of cancer to facilitate better outcome for cancer patients by
allowing the tailoring of individual therapy via the assessment of
progression and survival.
An elevated expression of SR-B1 has been observed in a wide
variety of malignant cell lines such as breast, prostate, ovarian,
pancreatic, nasopharyngeal, and colorectal cancers (Martin et al.,
1999; Cao et al., 2004; Shahzad et al., 2011; Twiddy et al.,
2012; Zheng et al., 2013). In human breast carcinoma, higher
SR-B1 protein levels were observed in malignant tissue versus
cancer free surrounding tissue in xenograft studies (Cao et al.,
2004). Moreover, mutation of the HDL receptor attenuated the
proliferation of MCF-7 cells (Cao et al., 2004). Similarly, another
study demonstrated that over 50% of all examined breast cancer
tissue showed a high expression of SR-B1 which significantly
correlated with larger size of the tumor, metastasis to lymph node,
and overall reduced survival (Yuan et al., 2016). Additionally,
breast carcinomas displaying higher SR-B1 mRNA and protein
levels showed enhanced accumulation of intratumor cholesteryl
ester which linked to aggressiveness and poor prognosis in
patients (de Gonzalo-Calvo et al., 2015). Likewise, knockdown
of SR-B1 significantly reduced tumor size in mouse models
and reduced cell proliferation and migration in vitro. This
study also identified a link between HDL-SR-B1 and Akt
where breast cancer cells stimulated with cholesteryl ester from
HDL exhibited continued proliferation, migration/invasion and
subsequent tumor growth (Danilo et al., 2013). Taken together
these studies reveal a critical role for SR-B1 as a prognostic
marker and therapeutic target for breast cancer treatment.
The uptake of cholesterol ester from HDL via SR-B1 facilitates
many important cellular functions such as the production of
androgens. Thus, a knockdown of SR-B1 was shown to diminish
prostate-specific antigen (PSA) levels and cell viability in prostate
cancer cells (Twiddy et al., 2012). Using mRNA microarray
files and immunohistochemical analysis of prostate cancer tissue
sections Schörghofer et al. (2015) found that mRNA and protein
SR-B1 expression positively correlated with progression and
metastasis of prostate cancer. The study revealed a higher SR-
B1 expression in higher Gleason grade prostate tumors than
in lower Gleason grade prostate tumors (Schörghofer et al.,
2015). Additionally, SR-B1 expression and enzymes involved
in the synthesis of androgens exhibited a positive correlation
indicating that SR-B1 may have a potential role in establishing
androgen independence (Schörghofer et al., 2015). Moreover, in
nasopharyngeal cancer (NPC) SR-B1 was overexpressed in 75% of
clinical NPC samples and all examined NPC cell lines while SR-
B1 expression was lower in surrounding non-malignant epithelial
cells suggesting SR-B1 as a possible biomarker of NPC (Zheng
et al., 2013).
Interestingly the generation of Kaplan–Meier survival curves
using the R2 Genomics Analysis and Visualization Platform1
1http://r2.amc.nl
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along with publicly accessible microarray data confirmed the
correlation of high SR-B1 expression and poor prognosis in
neuroblastoma, Ewing sarcoma, bladder, breast, and myeloma
cancers (Pawitan et al., 2005; Hanamura et al., 2006; Molenaar
et al., 2012; Sjodahl et al., 2012). However, a reverse was observed
in cancers such ovarian, osteosarcoma, B-Cell lymphoma, and
lung (Bild et al., 2006; Kuijjer et al., 2012; Lisowska et al., 2014),
specifically low SR-B1 correlated with poor survival. Given the
complexities involved in the regulation of SR-B1 expression it is
difficult to hypothesize regarding mechanism(s) involved in the
observed variations of SR-B1 expression in relation to patient
survival. Perhaps transcription factors such as p53, STAT proteins
and c-myc could play a role in the regulation of SR-B1 expression
(Gutierrez-Pajares et al., 2016) thus impacting carcinogenesis
and metastasis. Alternatively, microRNAs such as miR-125 and
miR455 may decrease the expression of SR-B1 mRNA and protein
levels in malignant tumors as they do in steroidogenic tissue (Hu
et al., 2012). Consequently, all these factors (alone or together)
could account for the observed variations in SR-B1 expression
and its correlation with overall patient survival.
SR-B1 AS A GATEWAY FOR DRUG
DELIVERY
The first definitive role for HDL in reverse cholesterol transport
as a promoter of the excess cholesterol from peripheral cells to
the liver was proposed by Glomset (1968). In this process, the
cholesterol from the circulating HDL particles can be taken up
via receptor-mediated mechanisms, either directly from HDL
through SR-B1 or by the LDL receptor, subsequent to the transfer
of cholesteryl esters from HDL (Besler et al., 2012). The major
difference in the uptake of HDL payloads via LDL and SR-B1
receptors is that the LDL mediated operation is endocytotic (non-
specific) whereas SR-B1 mediated uptake is non-endocytotic
(highly specific). In the later process, the lipoprotein specifically
binds to the cell surface and delivers the hydrophobic cargo
directly inside the cells, without internalizing the lipoprotein
shell. This mechanism bypasses the reticulo endothelial system
and lysosomal exposure of the payload (including drugs) and
is, therefore, preferred compared with the endocytotic process
utilized by the LDL receptors for drug delivery (Bricarello et al.,
2011; Ng et al., 2011; Cruz et al., 2013; McMahon et al., 2015).
Due to their unique structure of a phospholipid monolayer
stabilized by a protein component, covering a firm inner
hydrophobic core, lipoproteins and especially HDL, are
considered as natural nanocarriers to harbor and transport
hydrophobic compounds, including anti-cancer drugs to cancer
cells and tumors via the SR-B1 gateway. (Counsell and Pohland,
1982; Bijsterbosch and van Berkel, 1990; Bijsterbosch et al.,
1994; Firestone, 1994; Lacko et al., 2007; Bricarello et al.,
2011). Silvente-Poirot and Poirot (2012) have demonstrated
that carcinogenesis and tumor development have a dramatic
impact on alterations in cholesterol metabolism of the cells.
As a repercussion, there is an enhanced expression of SR-B1
receptors in most malignant cells (Shahzad et al., 2011) to
meet their cholesterol needs for enhanced proliferative rates
(Mooberry et al., 2010; Ng et al., 2011; Shahzad et al., 2011;
Zheng et al., 2013). Thus the SR-B1 receptor has a great potential
to be a biomarker of different types of cancers. Several studies
have shown that malignant cells have an elevated requirement
for cholesterol resulting in reduced HDL cholesterol levels
in cancer patients, as compared with healthy subjects (Lacko
et al., 2007; Ng et al., 2011). Using a quantitative real-time PCR
technique, Shahzad et al. (2011) have demonstrated considerable
increase in the expression of SR-B1 receptors in most tumor
samples of breast, ovarian, colorectal and pancreatic cancer
compared with those of normal tissues (Shahzad et al., 2011).
The SR-B1 mediated process has also been shown to function
in the uptake of anticancer agents from reconstituted high
density lipoprotein (rHDL) by cancer cells (McConathy et al.,
2008; Mooberry et al., 2010; Sabnis et al., 2012; Shen et al.,
2014; Song et al., 2015). An enhanced uptake of paclitaxel from
rHDL nanoparticles was demonstrated in SR-B1 overexpressing
prostate cancer cells by Mooberry et al. (2010) where the SR-B1
mediated entry of the drug represented 82% of the total paclitaxel
incorporation by these cells. In another study, using a construct
of a synthetic HDL-gold nanoparticle template, Yang et al. (2013)
showed that similar to natural HDLs, biomimetic HDL-NPs
can be formulated to target SR-B1 receptors in lymphoma cells.
Furthermore, by differential manipulation of SR-B1 binding
and restricting cholesterol delivery they showed induction of
apoptosis in lymphoma cells (Yang et al., 2013).
SR-B1 AS A CONDUIT FOR THE
DELIVERY OF IMAGING AGENTS
Due to their capacity for incorporating preferentially
hydrophobic compounds in their core region, lipoproteins
have been well-recognized as platform for delivering theranostic
agents. rHDL-like particles have been developed for imaging of
atherosclerosis by contrast enhanced MRI (Frias et al., 2004).
In this study, ApoA-I, extracted from human plasma, was
reconstituted with commercially available phospholipids, which
was coupled with a gadolinium (Gd)-chelate, making the particle
visible for MRI. Furthermore, a green-emitting and amphiphilic
fluorophore, 7-nitro-2-1,3-benzoxadiazol-4-yl (NBD-DPPE) was
included in the lipid monolayer, to enable its detection with
fluorescence techniques. MRI scans of the abdominal aorta of
the apo E knock out mice injected with this preparation revealed
significant accumulation of rHDL in the aortic wall. Extending
this approach, Cormode et al. (2008) developed a synthetic
HDL/apoA-I mimicking nanoparticle composed of lipids and
an apo A-I derived, amphiphatic α-helical peptide, 37pA. These
nanoparticles were formulated with Gd-chelates and a lipid-
based fluorophore, rhodamine-PE, into the phospholipid layer,
making the particles suitable for MRI and fluorescence imaging.
Skajaa et al. (2010) employed rHDL as a vector for delivering a
variety of diagnostic agents to susceptible atherosclerotic plaques
in a mouse model. They showed that by loading various types
of image-enhancing compounds into either the core or surface
of rHDL nanoparticles, they can be visualized by different
imaging modalities (MRI, CT, optical). These findings suggest
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that imaging of pathological processes other than atherosclerosis
may also be accomplished using rHDL as a carrier.
Fluorescence based studies reported by Shah et al. (2016)
showed that the drug valrubicin has differential optical properties
when encapsulated in rHDL. Moreover, valrubicin has low
quantum yield in aqueous environment and it increases several
fold when incorporated into rHDL nanoparticles. Further, they
showed that the rHDL-valrubicin formulation could be used for
confocal imaging in a SR-B1-positive prostate cancer cell line.
These studies reveal the potential of HDL type nanoparticles
to deliver a cargo of theranostic agents via SR-B1 receptors; thus
further emphasizing the role of the SR-B1 receptors in facilitating
the delivery of imaging agents.
CANCER THERAPEUTICS:
CHALLENGES AND NOVEL THERAPIES
Many of the currently employed cancer chemotherapeutic
drugs are associated with challenges, including solubility, bio-
distribution and tissue non-specificity (Farokhzad and Langer,
2009). The majority of anti-cancer drugs are also non-selective in
their bio-distribution as they affect all rapidly dividing cells thus
disseminating the drug into both healthy as well as malignant
tissues. Advances in nanotechnology and using targeted drug
delivery vehicles, have shown great potential to overcome these
challenges to effective chemotherapy. The therapeutic index of a
drug can be significantly improved by increasing the preferential
accumulation of the therapeutic agent in malignant cells while
protecting healthy cells and thereby reducing toxic side effects
(Rigotti et al., 2003; Foit et al., 2015; Lacko et al., 2015).
High density lipoprotein HDL-type nanocarriers exhibit many
features of an ideal drug-delivery vehicle. The particles have small
size, are biocompatible, non-immunogenic, have long circulating
half-life and exhibit selective delivery (Zheng et al., 2005). Thus,
HDL particle functionality is a primary tool for HDL-based
drug delivery strategies (Kypreos et al., 2013). The potential
of HDL-type nanoparticles for drug delivery was proposed by
Counsell and Pohland (1982); however, systematic studies on
this were first carried out by Kader and Pater (2002) after
20 years (Counsell and Pohland, 1982). They have reported that
loading anticancer drugs into HDL as well as LDL had minimal
effect on the properties of the complexes, while the encapsulated
drugs showed enhanced cytotoxicity toward human carcinoma
cells (Kader and Pater, 2002). It has been well documented
that tumor tissues are characterized by a leaky vasculature and
low lymphatic drainage, leading to unequal interstitial pressure
between different parts of the tumor (Wu et al., 2013; Omidi and
Barar, 2014). This pressure difference leads to uneven retention of
particles between the center of the tumor and its periphery. HDL
and HDL-like particles are believed to exhibit active targeting
via SR-B1 receptors instead of utilizing passive targeting through
the enhanced permeability and retention (EPR) effect (Bricarello
et al., 2011; Llaverias et al., 2011; Gorin et al., 2012; Danilo et al.,
2013; Huynh and Zheng, 2013).
Although numerous antineoplastic drugs have shown promise
during pre-clinical studies, the success rate of these drugs
clearing clinical trials is extremely low. This is primarily due
to the off target effects that many of these agents exhibit
against peripheral (normal) tissues2. The selective delivery of
hydrophobic drugs, specifically to malignant tumors is facilitated
by SR-B1 receptor, and thus makes the rHDL drug-delivery
system unique and a potential enhancer of cancer therapeutics.
Lou et al demonstrated a preferential cytotoxicity of the
antineoplastic drug aclacinomycin encased in rHDL toward
malignant cells (Lou et al., 2005). Sabnis et al. (2012) found
that valrubicin when encapsulated into rHDL nanoparticles
was effective 1.8 and 2.6 times lower minimum inhibitory
concentrations (IC50) than the free drug against prostate and
ovarian cells, respectively. The valrubicin/rHDL formulation was
also found to have reduced toxicity toward non-malignant cells,
demonstrating the selective tumor delivery capabilities of rHDL
nanoparticles. In the past 10 years, scientists are realizing the
potential of HDL and HDL mimetic drug delivery strategies in
cancer theranostics, primarily due to the interaction of these
nanoparticles (Figure 1) with the SR-B1 receptor (McMahon
et al., 2011; Jia et al., 2012; Rui et al., 2013; Zheng et al., 2013;
Dong et al., 2014; Fischer et al., 2014).
FUTURE OPPORTUNITIES FOR THE
DEVELOPMENT OF CANCER
BIOMARKERS, THERAPY AND IMAGING
Traditional chemotherapy has always been aﬄicted with long
term and short term unpleasant side effects. In some cases
the side effects are worse than the disease itself. It is well
documented by different research groups now that malignant
cells consistently overexpress SR-B1 receptors as compared to
normal cells. Lipoprotein-based technologies could address the
above concerns via their ability to selectively deliver their payload
to cancer cells and tumors. Safety of apoA-1 containing HDL-
type formulations for human systemic administration has been
confirmed by numerous clinical studies (Lacko et al., 2002;
Kuai et al., 2016). Additionally, these formulations have a
potential to reposition several drugs that have been considered
as anticancer drugs but have been disapproved due to poor
solubility and excessive peripheral toxicity. This strategy could be
commercially beneficial, in contrast with conventional drug- and
target-screening strategies.
If determination of SR-B1 expression levels is included as
a pretest before starting the chemotherapy regimen, the HDL
based drug delivery could be tailored to respective cancer patients
with high SR-B1 expressing tumors. Alternatively for low SR-B1
expressing patients, specific functionalized rHDL nanoparticles
could be designed that will target different overexpressing tumor
antigens. Thus the oncogenic drugs could be rerouted from the
natural lipoproteins receptors thereby personalizing HDL-based
therapeutics.
Although the concept of using lipoproteins as targeted drug-
delivery agents was introduced back in 1982, and the suitability of
2https://www.bio.org/media/press-release/new-study-shows-rate-drug-
approvals-lower-previously-reported-0
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their functional characteristics for pharmaceutical formulations
was well known, there are currently no lipoprotein-
based drug delivery formulations in clinical trials or
in clinical use. However, considering their versatility
and selective-targeting capability, biofunctional HDL-type
nanoparticles are likely to bring a shift in the paradigm of
next generation cancer theranostics. The SR-B1 receptor-
mediated gateway of lipophilic anticancer drugs or imaging
agents via HDL and HDL-mimetic nanoparticles has
strengthened the potential for these preparations as theranostic
agents.
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